Rhabdomyosarcoma Market Report 2020 with Key Players, Regions, Trends, Market Growth, SWOT Analysis and Forecast to 2027

 The global rhabdomyosarcoma industry is expected to grow significantly over the forecast period. It is estimated that the global rhabdomyosarcoma market is expected to register a CAGR ~ 4.8 % during the forecast period of 2018–2023. Rhabdomyosarcoma is a type of cancerous tumor that starts to develop in the soft tissues of the body. Cells affected by rhabdomyosarcoma can grow and spread very fast.

Numerous factors such as raising awareness of rhabdomyosarcoma and its increasing prevalence are expected to drive the growth of the market.

Moreover, favorable healthcare investments by government and the rising demand for better treatments boosts the growth of the market. However, stringent government regulation for product approval and huge costs of the treatment may hamper the market growth during the assessment period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6569 

Regional Analysis

The market in the Americas is expected to dominate the global rhabdomyosarcoma market during the forecast period owing to the high prevalence of rhabdomyosarcoma and well-established healthcare infrastructure. According to an article published by the American Society of Clinical Oncology in January 2018, about 350 children are diagnosed with rhabdomyosarcoma every year. The European market is expected to be the second-largest due to the well-developed healthcare infrastructure in the region. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the assessment period owing to favorable government initiatives for enhancing healthcare facilities. The market in the Middle East & Africa is likely to account for the smallest share of the global rhabdomyosarcoma market. The market growth in this region can be attributed to the increases cases of rhabdomyosarcoma.

Segmentation

The global rhabdomyosarcoma market has been segmented into type, treatment, and diagnosis.

The market, on the basis of type, has been segmented into Embryonal Rhabdomyosarcoma, and Alveolar Rhabdomyosarcoma. Alveolar rhabdomyosarcoma is expected to account for the largest market share in this segment owing to its rising prevalence. It is also anticipated to be the fastest growing market.

The market, by diagnosis, has been segmented into Imaging Tests and Biopsy.

According to diagnosis, imaging tests have been segmented into X-Ray, CT scan, MRI scan, PET scan, and Bone scan.

According to diagnosis, biopsy has been segmented into Needle Biopsy and Surgical Biopsy.

The market, by treatment, has been segmented into Surgery, Radiation Therapy, Chemotherapy and Stem Cell Therapy.

Key Players

Some of the key players in the global rhabdomyosarcoma market are Eli Lilly & Company, Boehringer Ingelheim International GmbH, Pfizer Inc, Novartis AG, Bristol Myers Squibb Company, Oasmia, Bellicum Pharmaceuticals, Inc., CELGENE CORPORATION, Eisai Co., Ltd., MacroGenics, Inc., NantKwest., TAIHO ONCOLOGY, INC., Tarveda Therapeutics., Exelixis, Inc., and Ipsen Pharma.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/rhabdomyosarcoma-market-6569 

 

Oral Thin Film Drugs Market: Segmentation, Industry trends and Development to 2027

 Oral thin films (OTF) are an innovative method discovered by pharmaceutical scientists for delivering drugs orally or bucally (absorption or dissolution in the mouth). OTF drugs have gained popularity owing to its rapid dissolution on contact with saliva. The global oral thin film drugs market is predicted to exhibit an 8.10% CAGR from 2019 to 2027 (forecast period), as per the latest report by Market Research Future (MRFR). This can be credited to the expanding geriatric population and their need for advanced drug delivery methods to keep chronic diseases such as diabetes at bay. Continuous investment in research and development (R&D) by companies to create easily dissolvable solutions for other diseases is expected to spur market growth over the forecast period. Introduction of OTF drugs in developing countries can act as a good revenue source for the OTF drugs market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6547 

Segmentation:

The oral thin film drugs industry can be segmented by product, disease indication, and distribution channel.

By form, the market is segmented into fast dissolving buccal film and sublingual. The fast dissolving film segment accounted for 58% share in the oral thin film drugs market in 2017. This can be credited to the potential of OTF drugs in dissolving rapidly and its efficacy and safety. It can enjoy good dividends at a 11.31% CAGR over the forecast period. On the other hand, the sublingual segment can enjoy a 9.34% CAGR to touch a valuation of USD 1,622.3 million by 2023.

By disease indication, the market is segmented into migraine, schizophrenia, opioid dependence, and nausea and vomiting, and others. Among these, the schizophrenia segment accounted for 36% market share in 2017. It can generate market demand at a 10.34% CAGR over the forecast period. On the flip side, the migraine segment can grow at a robust pace owing to high prevalence of migraine attacks.

By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online drug stores, and others. The retail pharmacies segment accounted for 46.9% market share in 2017.  This can be attributed to the increasing patient population and their respective treatment at hospitals. In addition, the low cost of drugs at these pharmacies compared to hospital pharmacies can thrust the segment valuation to USD 1,930.9 million by 2023. But the online drug stores segment is expected to generate returns at a 11.66% CAGR over the forecast period.

Regional Analysis:

The oral thin film drugs market covers the latest trends and opportunities across Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

The Americas accounted for the lion’s share of the market in 2017 owing to the presence of well-known players in the healthcare sector, increased healthcare expenditure of nations such as the U.S., and sophisticated healthcare expenditure. According to the World Health Organization (WHO), the population of North America can expand at 42% from 2000 to 2050 and this can have a noticeable impact on the market. The mushrooming of retail pharmacies to cater to demands of patients can propel the Americas market to grow at a 10.72% CAGR during the forecast period.

The Europe oral thin film drugs market can experience a 9.44% CAGR over the forecast period owing to supportive government fiats and healthcare funds. Strong economies of France, Germany, and the U.K. can contribute to market revenue till 2023.

The APAC region is touted to experience a robust growth rate owing to developing economies, changing healthcare sector, and increasing geriatric population. It can touch a valuation of USD 543.3 million by 2023. This can be credited to fast-moving economies of India, Japan, and China.

The MEA region may experience a sluggish growth rate owing to slow economic growth of countries in Africa.  But well-developed countries such as Kuwait, Qatar, and the United Arab Emirates (UAE) and their increased healthcare budgets can drive the regional market growth over the forecast period.

Competitive Dashboard:

Prominent players operating in the oral thin film drugs market include Novartis AG (Switzerland), Indivior Plc (U.S.), LTS Lohmann Therapie-Systeme AG (Germany), GlaxoSmithKline Plc (U.K.), CURE Pharmaceutical (U.S.), Pfizer Inc. (U.S.), and Johnson & Johnson Services, Inc. (U.S.).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/oral-thin-film-drugs-market-6547 

 

Spirometry Market Current Trends, SWOT Analysis, Strategies, Industry Challenges, Business Overview and Forecast Research Study 2027

 Spirometry is a test that is conducted by various clinicians that help in the evaluation of the lung status of an individual. This is more important for the diagnosis of asthma, along with other breathing issues. These tests for the lung and related-breathing issues are done with the help of spirometers. The rise of respiratory diseases in the aging population, along with the technological shift in the devices towards the data acquisition that is smartphone-based is working well for the global expansion of the spirometry market size. 

Initially, budget constraints were covering the healthcare sector, but, with the increase in investments, and advancement in technology, good growth for the spirometry market is expected in the future forecast year of 2023. Also, the acute rise in cases of asthma, and chronic obstructive pulmonary disorders (COPD), are helping in expansion. The market is expected to exhibit a growth of 10.03% CAGR, by the end of the forecast period of 2019-2023. The spirometry market valuation is expected to reach USD 1,106.76 million. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6539 

Segmentation:

The spirometry market can be segmented by product, technology, application, and end-user.

By product, the market is segmented into table-top spirometry, hand-held spirometry, and desktop (PC) spirometry. The table-top spirometry segment accounted for 49.9% market share in 2017, followed by hand-held (31%), and desktop (19.1%). This can be attributed to adoption of spirometers in hospitals and clinics. But the desktop segment is touted to register the highest CAGR of 10.58% during the forecast period owing to its rapid diagnosis rate and increasing use of computer-based applications.

By technology, the market covers flow measurement spirometry, volume spirometry, and peak flow meters (PFM). The flow measurement spirometry segment accounted for 50.3% share in 2017. This can be attributed to its lightweight nature and compact size. Its functionality based on the familiar table-top spirometer technology and lack of frequent calibration make it popular among clinicians. But the PFM technology can register 10.58% CAGR over the forecast period to reach USD 149.76 million by 2023.

Major applications of the spirometry market include diagnostic and treatment monitoring. The diagnostic segment is further sub-segmented into asthma, interstitial pulmonary fibrosis, and COPD. The diagnostic segment accounted for 68.93% share of the market in 2017, spurred by the prevalence of breathing diseases such as asthma. But the treatment monitoring segment can exhibit the highest CAGR during the review period to reach a valuation of USD 353 million by 2023. Its valuation in 2018 was suggested to be USD 214.12 million.

Key market end-users include hospitals & clinics, research & academic institutes, diagnostic centers, and home care. The home care segment is projected to enjoy a 9.90% CAGR to reach a valuation of USD 71.14 million by 2023 from USD 44.38 million in 2018.

Regional Analysis:

The spirometry market covers the latest trends and opportunities across Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

The Americas accounted for 39.74% spirometry market share in the global market in 2017, followed by Europe and APAC. This can be attributed to economies such as the U.S. which are the earliest adopters of latest technologies coupled with the large patient pool suffering from respiratory disorders. The region is likely to enjoy a 10.25% CAGR over the forecast period.

The Europe spirometry market is expected to enjoy a CAGR similar to the Americas market over the forecast period to touch a valuation of USD 322.33 million by 2023. This can be credited to rising number of asthma cases and ballooned healthcare expenditure of nations such as Germany and France.

The MEA region can experience a respectable CAGR during the review period owing to improvements of healthcare infrastructure and enhanced healthcare budgets of Kuwait, Qatar, and Dubai.

The APAC region is expected to exhibit a 10.94% CAGR over the forecast period owing to high cases of chronic diseases, awareness of respiratory devices, and increased healthcare budgets of developed nations in the region. The growing geriatric populace in China and Japan can contribute to regional market revenue till 2023.

Competitive Dashboard:

Key players in the spirometry market include Smiths Medical Inc. (U.S.), Vitalograph (U.K.), MGC Diagnostics Corporation (U.S.), Hill-Rom Holdings, Inc. (U.S.), Schiller AG (Switzerland), COSMED srl (Italy), Midmark Corporation (U.S.), NDD Medical Technologies, Inc. (U.S.), Carefusion Corporation (U.S.), Nihon Kohden Corporation (Germany), and Koninklijke Philips N.V. (The Netherlands).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/spirometry-market-6539 

 

Global Benzathine Penicillin G Market 2020 Industry Key Players, Trends, Sales, Supply, Demand, Analysis & Forecast By 2027

 Benzathine Penicillin G is a formulation of two penicillin G molecules. Benzathine Penicillin G is a treatment used for various bacterial infections such as bejel, diphtheria, rheumatic fever, and also syphilis a sexually transmitted infection caused by the Treponema pallidum bacteria. Benzathine Penicillin G is also used to treat respiratory infections caused due to bacteria and viruses. It functions by inhibiting the growth of bacterial and viral infections in the human body. The key factors responsible for causing bacterial and viral infections are decrease in immunity due to change in lifestyle and having unhygienic food and other which supports the growth of the Benzathine Penicillin G market. According to the Centers for Disease Control and Prevention, December 2015, 21.2 million women of the age group of 14 to 49 years were affected by the bacterial vaginosis infection in the US. Such a high prevalence of bacterial infection can influence the market positively.

However, factors such as allergies and side effects associated with treatments are expected to restrict the market growth during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6541 

Segmentation

The global Benzathine Penicillin G industry  is segmented on the basis of application, mode of injection, and end user. The Benzathine Penicillin G market, by application, is segmented into bacterial infections and sexually transmitted infection (STI) syphilis therapy. Bacterial infections are further segmented into Bejel, diphtheria, and rheumatic fever.

On the basis of mode of injection, the market is segmented into intravenous and intramuscular injection. On the basis of end user, the global Benzathine Penicillin G market is segmented into hospitals and clinics, diagnostic centers, ambulatory surgical centers, research centers, and others.

Regional Analysis

The Americas is the largest in the market owing to the increasing prevalence of rheumatic heart disorders and growing healthcare expenditure. According to the National Meningitis Association December 2014, every year approximately 600 to 1000 people are affected by the meningococcal disease in the US. Such a high incidence rate of meningococcal disease drives the market growth in this region.

Europe (UK, Belgium, France, and Netherlands) is expected to be the second largest Benzathine Penicillin G market during the forecast period. The increasing occurrence of sexually infective diseases positively drives the market in this region. According to the European Centre for Disease Prevention and Control, September 2015, it is estimated that every year approximately 146 million cases of sexually transmitted infections are found worldwide. In Europe, 385 000 cases were reported in 2013 which may increase during the forecast period. Thus, the growing cases of sexually transmitted infections facilitate market growth.

Asia-Pacific was projected to be the fastest growing region for the global Benzathine Penicillin G market in 2017. The market is expected to witness growth owing to the increasing awareness about the treatment and increasing research and development centers in this region.

The Middle East and Africa accounts for the lowest share due to lack of availability of well-trained healthcare professionals and low per capita income. However, the rising number of hospitals and healthcare services in the community are expected to support the market. In the region, some developing countries are rising their investments in research and development which is anticipated to contribute to the growth of the market.

Key Players

Some of the key players in the global Benzathine Penicillin G market are Abcam plc, Pfizer Inc, Alembic IT Department, ECPlaza Network Inc, Sandoz International GmbH, Merck KGaA, Triveni Interchem Private Limited, CSC Pharmaceuticals, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/benzathine-penicillin-g-market-6541 

 

Respiratory Care Devices Market: Recent Industry Trends and Projected Industry Growth, 2020– 2027

 The global respiratory care devices market growth is expected to register a significant growth at 10.1% CAGR during the forecast period (2018–2023).

The respiratory care devices are used for treatment, assessment, diagnosis, and care of patients suffering from cardiopulmonary devices. Respiratory care devices are used in the treatment of lung diseases such as chronic bronchitis, tuberculosis, acute and chronic pulmonary diseases, asthma, and others. With the growing age, the function of lungs starts to decline and hence the respiratory system undergoes various physiological, functional and immunological changes. The market growth is due to the rising incidences of chronic pulmonary diseases, asthma, and others. These devices can be used in hospitals and in-home care settings as they have developed from stationary to portable ones.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6517 

Factors such as the increasing frequency of respiratory diseases, increasing geriatric population, urbanization, and its adverse effects, and changes in the environment and lifestyle boosts the growth of the market. The growing demand for point-of-care diagnostic devices in developing regions is anticipated to provide new opportunities for players in the respiratory care devices market. The lack of awareness about respiratory problems, intense competition, and the cost associated with the device and the respiratory surgery hamper the growth of the market.

Segmentation

The global respiratory care devices market has been segmented on the basis of therapeutic devices, monitoring devices, diagnostic devices, accessories and consumables, application, and end-users. On the basis of therapeutic devices, the market has been classified as pap devices, masks, ventilators, nebulizers, humidifiers, oxygen concentrators, inhalers, reusable resuscitators, nitric oxide delivery units, and oxygen hoods. On the basis of monitoring devices, the market has been classified as pulse oximeters, pulse oximeter sensors, pulse oximeter equipment, capnographs, and gas analyzers. On the basis of diagnostic devices, the market has been classified as spirometers, polysomnography (PSG) devices, peak flow meters, and other diagnostic devices. On the basis of accessories and consumables, the market has been classified as disposable masks, disposable resuscitators, tracheostomy tubes, nasal cannulas, and other consumables and accessories. On the basis of application, the market has been classified as chronic obstructive pulmonary disease (COPD), sleep apnea, asthma, infectious diseases, and other diseases. On the basis of end-users, the market has been classified as hospitals, clinics, ambulatory care, home care, and others.

Regional Analysis

The Americas is projected to lead the respiratory care devices market during the forecast period. Increasing healthcare awareness, advancement in technology, and medical tourism are some other factors that boost the growth of the market. According to the statistics of Life and Breath, on an average 72 Canadians were diagnosed with lung cancer daily and 56 Canadians died from lung cancer on a daily basis in 2014.

The European market is expected to hold the second largest market share. According to the statistics of the British Lung Foundation in the year 2014, around 10,000 people in the UK are newly diagnosed with a respiratory disease every week. According to the statistics of the British Lung Foundation, lung diseases are accountable for more than 7,00,000 hospital admissions and over 6 million inpatient bed-days in the UK each year.

Asia-Pacific is projected to be the fastest growing region for the global respiratory care devices market in 2018. The market is expected to witness growth owing to the rising patient population, changing lifestyle, and growing elderly population. This is expected to provide favorable backgrounds for the market to grow. According to the Asia-Pacific Lung Cancer Conference (APLCC), 90% of the lung cancer cases are due to the rise in the consumption of tobacco.

The Middle East and Africa accounts for the least share due to stringent government policies and low per capita income.

Key Players

Some of the key players in the global respiratory care devices market are Philips Healthcare (The Netherlands), ResMed, Inc. (US), Medtronic plc (Ireland), Masimo Corporation (US), and Fisher & Paykel Healthcare Corporation Limited (New Zealand), Becton, Dickinson and Company (US), Chart Industries, Inc. (US), Drägerwerk AG & Co. KGaA (Germany), and Hamilton Medical AG (Switzerland).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/respiratory-care-devices-market-6517 

 

Wearable Injectors Market: Drivers, Restraints, Opportunities, and Threats (2020-2027)

 The global wearable injectors market is expected to grow significantly over the forecast period. It is estimated that the global wearable injectors market is expected to register a CAGR of ~ 15.2% during the forecast period from 2018 to 2023. Wearable Injectors are medical devices designed to dispense large doses of the drug. Wearable Injectors are user-friendly, convenient and they lessen the need for multiple painful injections.

Numerous factors such as growing demand of convenient methods of drug administration, rising prevalence of chronic diseases such as diabetes, technological advancements and design development in wearable injectors are expected to drive the growth of the market. For instance, in July 2016, Amgen received US Food and Drug Administration (FDA) approval for its on-body wearable injector, Repatha (evolocumab) Pushtronex system, a human monoclonal antibody injector.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6491 

Moreover, favorable healthcare investments by government and the rising demand for minimally invasive devices boosts the growth of the market. However, stringent government regulation for product approval and the growing preference for traditional methods of drug delivery may hamper the market growth during the assessment period.

Regional Analysis

The market in the Americas is expected to dominate the global wearable injectors Market trends during the forecast period owing to the presence of well-established healthcare infrastructure and advanced technologies to administer drugs for the treatment of chronic diseases like diabetes. According to the National Diabetes Statistics Report 2017, an estimated 30.3 million people of all ages had diabetes in the US in 2015. The European market is expected to be the second-largest due to the growing medical devices industry in France, Germany & the UK and the rising opportunities for the market players. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the assessment period owing to favorable government initiatives for the medical devices industry. The market in the Middle East & Africa is likely to account for the smallest share of the global wearable injectors market. The market growth in this region can be attributed to the rising research and development activities in the region.

Segmentation

The global wearable injectors market has been segmented into type, usage, mechanism of injection, therapeutic area, and end user.

The market, on the basis of type, has been segmented into on-body wearable injectors, off-body wearable injectors, and hand-held wearable injectors.

The market, by usage, has been segmented into disposable and semi-reusable.

The market, by mechanism of injection, has been segmented into spring based, motor driven, rotary pump, expanding battery, pressurized gas, and collapsible reservoir.

The market, by therapeutic area, has been segmented into oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes, and others.

The market, by end-user, has been segmented into hospitals, clinics, home care, ambulatory surgery centers, and others.

Key Players

Some of the key players in the global wearable injectors market are West Pharmaceutical Services, Inc., Valeritas, Inc., Eli Lilly and Company, YPSOMED, Amgen Inc., Becton, Dickinson and Company (BD), CeQur SA, SteadyMed Therapeutics, Inc., BioSpace, Enable Injections, and Sensile Medical AG.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/wearable-injectors-market-6491 

 

Swollen Knee Treatment Market: Recent Industry Trends and Projected Industry Growth, 2020– 2027

 The global swollen knee treatment market is expected to register a significant growth during the forecast period (2018–2023).

Knee swelling or occasionally mentioned as “water on the knee” is a condition where excess fluid gets accumulated in an around the knee joint. This conditions in medical terms are referred to as “knee effusion”. The swollen knee can result due to injuries such as torn ligament, cartilage tear or broken bones. The increasing number of geriatric populations followed by the rising frequency of musculoskeletal diseases, a growing number of surgeries undertaken is projected to grow the global swollen knee treatment market. The operating procedure of knee replacement is inclusive of various steps taken to implant the artificial device and replacement of the damaged knee.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6406 

Segmentation

The global swollen knee treatment market has been segmented on the basis of type and end-users. On the basis of type, the market has been classified as medications, patient-controlled analgesia (PCA) pumps, nerve blocks, liposomal bupivacaine, and surgery. The medications have been segmented into opioids and corticosteroids and others. The surgery is segmented into arthrocentesis, arthroscopy and knee replacement. The knee replacement is further segmented into total knee replacement, unicompartmental knee replacement, and others. On the basis of end-users, the market has been classified as hospitals, clinics, ambulatory surgery centers, and others.

Regional Analysis

The Americas is projected to lead the swollen knee treatment market in the forecast period. Rising rate in a number of surgeries due to factors such as accidents, injuries, and others contribute majorly to the growth of the market. Increasing healthcare awareness, advancement in technology, medical tourism, and an increase in disposable income are some other factors that boost the growth of the market.

The European market is expected to hold the second largest swollen knee treatment market share as osteoarthritis is most common in Germany. The European market is projected to grow because of the increase in elderly population, growing prevalence of diabetes, and obesity in the region.

Asia-Pacific was projected to be the fastest growing region for the global swollen knee treatment market. The market is expected to witness growth owing to the rising patient population, changing lifestyle, and growing elderly population. This is expected to provide favorable backgrounds for the market to grow.

The Middle East and Africa accounts for the least share due to stringent government policies and low per capita income.

Key Players

Some of the key players in the global swollen knee treatment market are Stryker Corporation, Zimmer Holdings, Smith & Nephew Plc., DePuy Companies Inc., Wright Medical Group Inc., Biomet Inc., Exactech, B. Braun Melsungen AG, Pfizer Pharmaceuticals Inc., Merck & Co., Fresenius Kabi, AngioDynamics , C.R.Bard ,Teleflex, and Smiths Medical

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/swollen-knee-treatment-market-6406